DiaSorin (OTCMKTS:DSRLF – Get Rating) was downgraded by investment analysts at BNP Paribas from a “neutral” rating to an “underperform” rating in a research note issued to investors on Thursday, Briefing.com reports.
A number of other brokerages have also issued reports on DSRLF. Stifel Nicolaus began coverage on DiaSorin in a research note on Tuesday, November 29th. They issued a “hold” rating for the company. HSBC upgraded DiaSorin from a “hold” rating to a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $143.00.
DiaSorin Stock Performance
OTCMKTS:DSRLF opened at $132.90 on Thursday. DiaSorin has a one year low of $107.00 and a one year high of $175.20. The business has a fifty day moving average price of $132.83 and a 200-day moving average price of $128.98.
DiaSorin Company Profile
DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The firm specializes in the immunodiagnostics and molecular diagnostics segments. It provides clinical services in the areas like Infectious Diseases, Bone and Mineral, Endocrinology, Hypertension, Oncology, Stool Diagnostics and Autoimmunity.
- Get a free copy of the StockNews.com research report on DiaSorin (DSRLF)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.